Stem cell transplantation for patients with Fanconi anemia with low-dose cyclophosphamide and antithymocyte globulins without the use of radiation therapy

Bone Marrow Transplant. 2005 Mar;35(5):463-6. doi: 10.1038/sj.bmt.1704787.

Abstract

In all, 22 patients with confirmed Fanconi anemia (FA) underwent stem cell transplantation (SCT) from HLA-matched, related donors at KFSHRC. Median age at SCT was 7.6 years (range, 2.5-14.6 years). Conditioning regimen consisted of cyclophosphamide (CY) 15 mg/kg/day intravenously (i.v.) for 4 consecutive days, in addition to equine antithymocyte globulins (ATG) given i.v. at 40 mg/kg/day for four doses pre-SCT. No radiation therapy was given. For graft-versus-host disease prophylaxis, we used cyclosporin at the standard doses; ATG was added at 20 mg/kg/dose i.v. on days 2, 4, 6, 8, 10, and 12 post-SCT (total of six doses). All patients engrafted and are alive and transfusion independent with a median follow-up time of 20.2 months (range, 3.3-59 months). One patient however developed a decrease in her WBC and platelet count. Her work-up revealed slightly hypocellular bone marrow, and a series of chimerism studies over 1 year confirmed that she has stable mixed chimerism; she remains transfusion independent. We conclude that low-dose CY without radiation therapy can be used satisfactorily in the conditioning of patients with FA undergoing related SCT.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Antilymphocyte Serum / administration & dosage*
  • Child
  • Child, Preschool
  • Cyclophosphamide / administration & dosage*
  • Fanconi Anemia / complications
  • Fanconi Anemia / therapy*
  • Female
  • Follow-Up Studies
  • Graft Survival
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Infections / drug therapy
  • Male
  • Survival Rate
  • Transplantation Conditioning / methods
  • Transplantation, Homologous

Substances

  • Antilymphocyte Serum
  • Cyclophosphamide